4P

4P-Pharma is a French clinical-stage biotechnology company focused on developing curative therapies for serious diseases with high unmet medical needs. The company employs a unique business model that sources early-stage academic innovations and accelerates them through preclinical and clinical development. Its lead candidate, 4P004, is a potential disease-modifying treatment for osteoarthritis currently in Phase 2 clinical trials. 4P-Pharma also advances programs in respiratory distress and oncology, including 4P021 for ARDS. Headquartered in Lille, the company leverages strategic partnerships with research institutions to build a robust pipeline of regenerative and anti-inflammatory medicines.